TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06351527: Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malign

Sponsor: InnoCare Pharma Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 78 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$857,888

Rescue Site Savings

+$564,400

Unlock Full NCT06351527 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06351527 Rescue Dossier →